ANIXA BIOSCIENCES, INC. Revenue from Contract with Customer, Excluding Assessed Tax
ANIXA BIOSCIENCES, INC. (ANIX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $210.00 thousand for the 12-month period ending 2023-10-31, per its 10-K filed 2025-01-10.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-01-10
- ANIXA BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-10-31 was $0.00.
- ANIXA BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-07-31 was $0.00.
- ANIXA BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-04-30 was $210.00K.
- ANIXA BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-10-31 was -$1.00K.
- ANIXA BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $210.00K.
- ANIXA BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $512.00K.
- ANIXA BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $250.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-10 | $0.00 derived: sum of 2 quarters · filed 2025-01-10 | $210.00K derived: sum of 3 quarters · filed 2025-01-10 | $210.00K 10-K · filed 2025-01-10 | ||||
| 2023-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-09-06 | $210.00K derived: sum of 2 quarters · filed 2024-09-06 | $210.00K 10-Q · filed 2024-09-06 | |||||
| 2023-04-30 | $210.00K 10-Q · filed 2024-06-04 | $210.00K 10-Q · filed 2024-06-04 | ||||||
| 2021-10-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-04 | -$1.00K derived: sum of 2 quarters · filed 2023-01-04 | -$1.00K derived: sum of 3 quarters · filed 2023-01-04 | $512.00K 10-K · filed 2023-01-04 | $512.50K 10-K · filed 2022-01-04 | |||
| 2021-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-09-09 | $0.00 derived: sum of 2 quarters · filed 2022-09-09 | $513.00K 10-Q · filed 2022-09-09 | $512.50K 10-Q · filed 2021-09-01 | ||||
| 2021-04-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-06-10 | $513.00K 10-Q · filed 2022-06-10 | $512.50K 10-Q · filed 2021-06-10 | |||||
| 2021-01-31 | $513.00K 10-Q · filed 2022-03-11 | $512.50K 10-Q · filed 2021-03-11 | ||||||
| 2019-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-01-07 | $250.00K 10-K · filed 2021-01-07 | ||||||
| 2019-07-31 | $250.00K 10-Q · filed 2020-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |